Trials / Unknown
UnknownNCT03550859
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 374 (estimated)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telmisartan/Rosuvastatin 40/10mg | Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks |
| DRUG | Telmisartan 40mg | Telmisartan 40mg qd for 48 weeks |
Timeline
- Start date
- 2018-06-05
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2018-06-08
- Last updated
- 2020-12-14
Locations
16 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03550859. Inclusion in this directory is not an endorsement.